Because SLU-PP-332 is studied in the context of enhancing mitochondrial function, increasing neuronal ATP production, and supporting synaptic energy demands, it is a subject in experiments related to cognitive metabolism and neuronal resiliencewithout implying outcomes outside of a research setting.
Since going public in 2021 through a $1.6 billion SPAC deal, its grown into a major telehealth company, expanding into mental health and dermatology although Hims continues to post videos about, well: On May 20, Hims announced it would also sell its own version of GLP-1 weight loss injections like Ozempic and Wegovy
43% were motivated to take better care of their appearance, and 29% expressed more confidence in social settings
This is why weight regain after stopping semaglutide is so common in the research, occurring in three to six months for many users
Members on the Microdose GLP-1 Rx Program have reported losing up to 17 pounds in 60 days